Back

Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in Long COVID

Al-Hakeim, H.; Abed, A. K.; Moustafa, S. R.; Almulla, A. F.; Maes, M.

2023-03-16 psychiatry and clinical psychology
10.1101/2023.03.11.23287152
Show abstract

BackgroundCritical COVID-19 disease is accompanied by depletion of plasma tryptophan (TRY) and increases in indoleamine-dioxygenase (IDO)-stimulated production of neuroactive tryptophan catabolites (TRYCATs), including kynurenine (KYN) and quinolinic acid. The TRYCAT pathway has not been studied extensively in association with the physiosomatic and affective symptoms of Long COVID. MethodsIn the present study, we measured serum tryptophan (TRY), TRYCATs, insulin resistance (using the HOMA2-IR index), C-reactive protein (CRP), physiosomatic, depression and anxiety symptoms in 90 Long COVID patients, 3-10 months after remission of acute infection. ResultsWe were able to construct an endophenotypic class of severe Long COVID (22% of the patients) with very low TRY and oxygen saturation (SpO2, during acute infection), increased kynurenine, KYN/TRY ratio, CRP, and very high ratings on all symptom domains. One factor could be extracted from physiosomatic symptoms (including chronic fatigue-fibromyalgia), depression, and anxiety symptoms, indicating that all domains are manifestations of the common physio-affective phenome. Three Long COVID biomarkers (CRP, KYN/TRY, IR) explained around 40% of the variance in the physio-affective phenome. The latter and the KYN/TRY ratio were significantly predicted by peak body temperature (PBT) and lowered SpO2 during acute infection. One validated latent vector could be extracted from the three symptom domains and a composite based on CRP, KYN/TRY, IR (Long COVID), and PBT and SpO2 (acute COVID-19). ConclusionThe physio-affective phenome of Long COVID is a manifestation of inflammatory responses during acute and Long COVID and lowered plasma tryptophan and increased kynurenine may contribute to these effects.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Brain, Behavior, and Immunity
based on 35 papers
Top 0.1%
13.2%
2
PLOS ONE
based on 1737 papers
Top 40%
12.7%
3
Acta Neuropsychiatrica
based on 11 papers
Top 0.1%
10.3%
4
Journal of Affective Disorders
based on 72 papers
Top 2%
5.4%
5
Translational Psychiatry
based on 94 papers
Top 3%
5.1%
6
Molecular Psychiatry
based on 84 papers
Top 2%
4.7%
50% of probability mass above
7
Scientific Reports
based on 701 papers
Top 42%
4.5%
8
Psychological Medicine
based on 52 papers
Top 3%
2.8%
9
Psychiatry Research
based on 33 papers
Top 2%
2.5%
10
Cells
based on 14 papers
Top 0.5%
1.9%
11
Journal of Psychiatric Research
based on 22 papers
Top 2%
1.6%
12
Brain, Behavior, & Immunity - Health
based on 11 papers
Top 0.3%
1.6%
13
Neuroscience & Biobehavioral Reviews
based on 19 papers
Top 2%
1.3%
14
Journal of Neurology, Neurosurgery & Psychiatry
based on 26 papers
Top 4%
1.3%
15
Frontiers in Psychiatry
based on 56 papers
Top 6%
1.2%
16
BJPsych Open
based on 24 papers
Top 2%
1.2%
17
Biological Psychiatry
based on 36 papers
Top 4%
1.2%
18
Nature Communications
based on 483 papers
Top 39%
0.8%
19
Journal of Personalized Medicine
based on 17 papers
Top 2%
0.8%
20
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
based on 27 papers
Top 3%
0.8%
21
BMJ Mental Health
based on 15 papers
Top 2%
0.8%
22
eBioMedicine
based on 82 papers
Top 6%
0.8%
23
Biological Psychiatry Global Open Science
based on 23 papers
Top 3%
0.8%
24
European Neuropsychopharmacology
based on 11 papers
Top 2%
0.8%
25
Psychoneuroendocrinology
based on 12 papers
Top 0.9%
0.7%
26
Neuropsychopharmacology
based on 29 papers
Top 3%
0.7%
27
Journal of Clinical Medicine
based on 77 papers
Top 18%
0.7%
28
Frontiers in Neurology
based on 74 papers
Top 12%
0.7%
29
Nature Medicine
based on 88 papers
Top 19%
0.7%